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Silk fibroin (SF) is an eligible biomaterial for the development of small caliber vascular
grafts for substitution, repair, and regeneration of blood vessels. This study presents the
properties of a newly designed multi-layered SF tubular scaffold for vascular grafting
(SilkGraf). The wall architecture consists of two electrospun layers (inner and outer)
and an intermediate textile layer. The latter was designed to confer high mechanical
performance and resistance on the device, while electrospun layers allow enhancing
its biomimicry properties and host’s tissues integration. In vitro cell interaction studies
performed with adult Human Coronary Artery Endothelial Cells (HCAECs), Human Aortic
Smooth Muscle Cells (HASMCs), and Human Aortic Adventitial Fibroblasts (HAAFs)
demonstrated that the electrospun layers favor cell adhesion, survival, and growth. Once
cultured in vitro on the SF scaffold the three cell types showed an active metabolism
(consumption of glucose and glutamine, release of lactate), and proliferation for up to
20 days. HAAF cells grown on SF showed a significantly lower synthesis of type I
procollagen than on polystyrene, meaning a lower fibrotic effect of the SF substrate.
The cytokine and chemokine expression patterns were investigated to evaluate the cells’
proliferative and pro-inflammatory attitude. Interestingly, no significant amounts of truly
pro-inflammatory cytokines were secreted by any of the three cell types which exhibited
a clearly proliferative profile. Good hemocompatibility was observed by complement
activation, hemolysis, and hematology assays. Finally, the results of an in vivo preliminary
pilot trial on minipig and sheep to assess the functional behavior of implanted SF-based
vascular graft identified the sheep as the more apt animal model for next medium-to-long
term preclinical trials.
Keywords: silk fibroin, small caliber vascular graft, morphological structure, mechanical performance, in vitro
biocompatibility, in vivo pilot test
Alessandrino et al. Small Caliber SF Vascular Graft
GRAPHICAL ABSTRACT | Novel hybrid textile-electrospun tubular architecture for vascular grafting, highly biocompatible, preventing fibrotic tissue responses,
promising off-the-shelf solution for treating vascular diseases.
INTRODUCTION
Cardiovascular pathologies are the leading cause of death
worldwide (World Health Organization, 2012), with very high
overall incidence on health expenditures. As the vascular diseases
progress with age, the related burden is likely to increase with
the global rise in life expectancy. Thus, the availability of grafts
for the treatment of vascular diseases becomes a real and urgent
need. In the vascular surgery field of either coronary or peripheral
bypass procedures, there is a crucial necessity of novel viable
solutions, which might complement or even replace current
surgical approaches, based on autografts, or synthetic grafts
(Catto et al., 2014; Hiob et al., 2017; Sugiura et al., 2017).
Autografts (using native vessels such as superficial veins or rarely
umbilical veins) still remain the standard clinical approach for
the replacement of small diameter blood vessels. However, there
are some factors which may strongly curb the use of autografts:
absence of a usable graft, significative atherosclerosis of the
arteries, previous usage of an autograft for surgical procedures,
or angiographic approaches (Catto et al., 2014).
Nowadays, small caliber synthetic grafts are made
of polyethylene terephthalate (PET) or expanded
polytetrafluoroethylene (ePTFE). Their use leads to possible
multiple complications like aneurysm, intimal hyperplasia,
calcification, thrombosis, infection, and lack of growth potential
for pediatric applications. These drawbacks are mainly correlated
to the regeneration of a non-functional endothelium and a
mismatch between the mechanical properties of grafts and
native blood vessels leading to the development of an intimal
hyperplasia with subsequent reduction of the patency rate (Catto
et al., 2014 and references therein cited).
As a biodegradable and biocompatible natural polymer Silk
Fibroin (SF) has the potential to become the biomaterial of
choice for the development of a range of medical applications,
including small caliber blood vessel grafts (Altman et al., 2003;
Thurber et al., 2015; Wang et al., 2017). The starting material
can be easily purified and processed in different 2D/3D shapes.
It is not immunogenic in humans (preliminary proteomic data
revealed that several human proteins expressed by both epithelial
and connective tissue cells exhibit homology sequences with SF
Armato et al., 2011) and favors angiogenesis, an essential feature
for tissue repair/regeneration (Dal Prà et al., 2005).
Manufacturing technologies of SF-based small caliber tubular
grafts span from filament winding (Enomoto et al., 2010;
Nakazawa et al., 2011), braiding (Ding et al., 2016; Zamani et al.,
2017), and knitting (Yagi et al., 2011; Yamamoto et al., 2016),
which are textile techniques making use of native microfiber
yarns as starting material, to electrospinning (Wang et al., 2010;
Liu et al., 2011; Xiang et al., 2011), and gel spinning (Lovett
et al., 2008, 2010), which lead to various formats of regenerated
SF tubular scaffolds. A recent research trend is to simulate
in the scaffold the three-layered structure of the native blood
vessel. Thus, designing multi-layered tubular scaffolds is seen as
an effective way to mimic not only the native architecture but
also to approach functional features of the artery. In particular,
the aim is to create regionally selective environments in favor
of the infiltration, adhesion, and spreading of cells conducive
to the regeneration of neo-tissues with biological features and
mechanical behaviors similar to the native ones.
The simplest technical approach to create at least an additional
layer is to coat the textile tubular scaffold with a film-
forming biocompatible polymer (SF or gelatin) (Fukayama et al.,
2015; Yamamoto et al., 2016). The use of SF microfibers as
scaffold material and of SF aqueous solution as coating showed
advantages in terms of enhanced in vivo endothelialization,
which corresponded to improved graft performance (e.g.,
medium-to-long term patency). Addition of crosslinking agents,
like poly(ethylene glycol diglycidyl ether), to aqueous SF
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enhanced stability, and protected the scaffold from rapid
degradation when implanted in vivo (Yagi et al., 2011).
Building a 3D sponge-like layer on one or both sides of the
tubular braided/knitted textile core may represent a step forward
in approaching more complex scaffold architectures (Aytemiz
et al., 2013; Liu et al., 2013, 2018; Ding et al., 2016; Zamani
et al., 2017; Tanaka et al., 2018). The manufacturing techniques
used by various authors, albeit with minor variations, share
common steps: immersion of the tubular textile core in a mold,
pouring a polymer solution, freeze-drying, and possible solvent
consolidation of the just created layer. Crosslinking agents can be
added to modulate porosity, strength, elasticity, and degradation
rate; functional molecules, most often anti-thrombogenic agents,
can also be loaded into the sponge. In vivo implantation up to 1
year in dogs (Aytemiz et al., 2013) and rabbits (Liu et al., 2018),
and up to 3 months in rats (Tanaka et al., 2018) resulted in high
patency rate, absence of thrombus, aneurysm, or infection, and a
physiological level of endothelialization of the internal lumen of
the graft with no signs of intimal hyperplasia.
The three-layered concept for the wall structure of the graft
was approached by Enomoto et al. (2010), who fabricated
a tubular scaffold by combining two kinds of native SF
microfibers, i.e., a thin silk thread and cocoon filaments, which
were successively arranged around a cylindrical core. The final
consolidation step consisted in dipping the scaffold into a
SF solution. The scaffold implanted into the abdominal aorta
of male Sprague-Dawley rats showed very good patency at 1
year, organization of endothelial and medial layers, formation
of vasa-vasorum in the adventitia, regenerating a vascular-like
structure. These findings highlighted the importance of SF as a
promising material to develop vascular grafts for smaller caliber
blood vessels.
Wu et al. (2018) and McClure et al. (2012) engineered
three-layered tubular scaffolds using only electrospinning
as the manufacturing technology. Combinations of natural
(SF, collagen, elastin) and biodegradable synthetic polymers
[polycaprolactone, poly(L-lactide-co-caprolactone), and
poly(lactide-co-glycolide)], alone or as blends, were used
to build layers with finely tuned morphological and
mechanical properties. The devices were fully characterized
from the mechanical point of view, but the authors
reported no in vivo functional tests. One of the devices
was subcutaneously implanted for 10 weeks in rats
(Wu et al., 2018) showing a propensity to promote cell
infiltration from the outside environment into the interior of
the graft.
Electrospinning has the ability to mimic the nanoscale
properties of fibrous components (collagen and elastin fibrils)
of the extracellular matrix and to realize a range of biochemical,
topographical, andmechanical properties conducive to improved
cell interactions (Babitha et al., 2017). Our previous studies
focused on the development of small caliber vascular grafts made
of electrospun SF (Marelli et al., 2009, 2010, 2012; Cattaneo
et al., 2013; Catto et al., 2015). SF tubular matrices with inner
diameter of about 5mm had a pressurized burst strength of
576 ± 17 mmHg, higher than physiological and pathological
pressure thresholds, but still lower than that of human arteries
(∼5,000 mmHg for carotids). The compliance value of about 3.5
(radial deformation/mmHg10−2) was considered very interesting
since it is higher than synthetic grafts (<2) and closer to the
physiological values for saphenous (4.4) and umbilical vein (3.7),
the gold standard for autologous replacement of small caliber
arteries. In vitro studies (Marelli et al., 2009, 2010, 2012; Catto
et al., 2015) showed good integration of cells with the SF matrix,
while functional implants in the abdominal aorta of Lewis rats
proved short term patency of the grafts (Cattaneo et al., 2013).
The cellular intimal thickening showed a structure similar to the
tunica of native arterial vessel, with elastin and intimal layers
reminiscent of the native inner vascular structure. Small blood
vessels with the morphology of vasa-vasorum were found in the
thin layer of tissue grown on the outer surface of the graft. Taken
together, all these results showed that small caliber SF vascular
grafts produced by electrospinning may be promising matrices
for vascular tissue replacement, without requiring cell seeding
before implantation.
This study reports the chemical, morphological, physical,
and mechanical properties of a novel multi-layered SF tubular
scaffold (SilkGraft). The hybrid architecture was designed to
optimize not only production and pre-surgery manipulation of
the device, but also stitching at the site of implantation, biological
integration with host’s tissues, and biomechanical performance
(compliance, resistance to radial stresses, biodegradation rate,
etc.). A wide range of in vitro cell interaction studies with
human adult fibroblasts, endothelial cells, and smooth muscle
cells were performed to investigate the biological response to
the device. The cytokine and chemokine expression patterns
were investigated to evaluate the cells’ proliferative and/or pro-
inflammatory attitude. The SilkGraft interaction with blood
components was studied by means of the complement cascade
activation assay, the change of the leucocyte and erythrocyte
counts, and the hemolysis assay. Additionally, the results of in
vivo preliminary pilot tests on large animals aimed at evaluating
the handling of the device during the surgical procedure and
identifying the more apt animal model for next medium-to-long
term preclinical trials will be presented and discussed.
MATERIALS AND METHODS
Fabrication of the Three-Layered Tubular
Scaffold
The vascular graft is a hybrid three-layered tubular device
comprising inner and outer electrospun layers (ES), and
an intermediate textile layer (TEX). The TEX layer was
manufactured by warp needle braiding technology using
degummed SF yarn. The ES nanofibrous layers were produced
via electrospinning using pupae-free silk cocoons as starting
material. Cocoons were degummed in autoclave at 120◦C for
30min and extensively washed with warm water. Pure SF
microfibers thus obtained were dissolved with an aqueous
solution of 9.3M lithium bromide at 60◦C for 3 h. The salt was
removed by dialysis and aqueous SF was cast in Petri dishes at
35◦C in a ventilated oven until complete evaporation of water
to produce SF films, which were then dissolved in Formic Acid
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(8% wSF/vFA) to prepare the spinning dope. Electrospinning was
performed as previously reported (Marelli et al., 2010) using
the following experimental parameters: voltage 25 kV, flow rate
0.8 ml/h, spinneret-collector distance 15mm. Coupling of TEX
and ES layers was made during electrospinning, according to a
patented process (Alessandrino, 2016), with the use of an ionic
liquid (1-ethyl-3-methylimidazolium acetate, Sigma Aldrich) as
welding agent. Hybrid ES-TEX-ES tubular devices were finally
purified by extraction with ethanol under microwave heating at
50◦C for 60min to remove processing aids, immersed in distilled
water overnight, dried, packaged under laminar flow cabinet, and
sterilized with ethylene oxide (EtO). Henceforth, the final three-
layered SF-based ES-TEX-ES vascular graft is identified by the
name “SilkGraft.”
Materials and Scaffolds Characterization
Morphological and Geometrical Properties
Morphological analyses were performed with a scanning electron
microscope (SEM; Zeiss EVO MA10) on Au/Pd sputter-coated
samples (Desk IV, Denton Vacuum, LLC), at 10 kV acceleration
voltage, 100 µA beam current, and 15mm working distance.
Geometrical properties of SilkGraft were characterized by
determining the weight per unit length, the wall thickness, and
the inner diameter. Wall thickness was measured according to
the ISO 7198:2016 standard method. The tubular device was cut
longitudinally, flattened and measured with a thickness tester
MarCator 1075R (Mahr) equipped with a constant load thickness
gauge of 1 cm2 foot area that exerts a pressure of 1 kPa.
Dry state inner diameter was determined from SEM images of
tubular cross-sections mounted on stubs, using the SEM software
measuring tools.
Amino Acid Analysis
The amino acid composition was performed after hydrolysis
with HCl 6N, under vacuum, for 24 h. Free amino acids were
quantitatively determined by Ion Exchange Chromatography
using external standard calibration. Samples were analyzed
in duplicate.
Attenuated Total Reflectance Fourier Transform
Infrared Spectroscopy (ATR-FTIR)
ATR-FTIR spectra were made with an ALPHA FTIR
spectrometer equipped with an ATR Platinum Diamond
accessory, at a resolution of 4 cm−1, in the infrared range of
4,000–400 cm−1. Spectra were corrected with a linear baseline
and normalized to the CH2 bending peak at about 1,445
cm−1. This peak was selected because it’s not sensitive to SF
molecular conformation.
Differential Scanning Calorimetry (DSC)
Thermal analyses were performed with a DSC 3500 Sirius
(Netzsch). Samples (3–5mg) were closed in Aluminum pans and
subjected to a heating cycle from 50 to 400◦C, at a heating rate of
10◦C/min, under N2 atmosphere (flow rate: 20 ml/min).
Circumferential Tensile Tests
Tests were performed according to ISO 7198:2016 using an All
Electric Dynamic Test Instrument ElectroPuls E3000 (Instron),
equipped with a load cell of 250N, a thermostatic bath (BioPuls),
and appropriate grips fabricated ad hoc. Samples (length =
10mm, n = 3) were cut carefully, mounted on the grips,
conditioned in water at 37◦C for 5min, and tested while
submerged at a crosshead speed of 50 mm/min. Due to the
difficulty in determining the correct size of the resistant cross-
sectional area, the results are expressed in terms of load and not
of the usual stress values.
Pressurized Burst Strength
The test was carried out according to ISO 7198:2016. A balloon
was placed inside the tubular graft (length = 100mm; n = 3)
and filled with test fluid at a measured rate of pressure change
until the sample burst or test was discontinued. Before testing,
samples were conditioned in the test fluid (distilled water) at
37◦C for 20min. No sample pre-stretching was applied, but axial
displacement (axial elongation of the sample) was allowed. The
test was performed with the sample submerged in the testing
fluid. A gear pump provided a flow through the sample and
pressure was measured just upstream the sample. The rise in
pressure and the pressure at which sample burst or test was
discontinued were measured and recorded.
In vitro Cellular Studies
Preparation of Substrates for in vitro Cell Cultures
SilkGraft samples were washed, transversally cut into 1.5 cm long
pieces, and opened lengthwise in order to obtain small squares
with an apparent surface area of about 300 mm2. After autoclave
sterilization (121◦C for 30min), they were aseptically transferred
to 2.2 cm-diameter culture plates (Falcon-Becton Dickinson).
Heat-sterilized stainless-steel rings were applied onto the upper
surface of the pieces to keep them flat at the bottom of the plates.
Pre-culture Intravital Cell Staining
Cells were stained with fluorescent lipophilic membrane dyes
(tracers) such as the red-orange fluorescent DilC18(3) (1,1’-
Dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate;
maximum fluorescence excitation 549 nm and emission 565 nm;




maximum fluorescence excitation 484 nm and emission 590 nm;
Thermo Fisher Scientific, USA) dissolved in DMSO according to
seller’s instructions. At intervals of 3 days, cultured specimens
were observed under an inverted fluorescence microscope (IM
35, Zeiss) equipped with proper excitation and emission filters
according to the intravital stain used, and digitally photographed
with a DP10 Camera (Olympus, Japan).
Cell Cultures
Adult Human Coronary Artery Endothelial Cells (HCAECs),
Human Aortic Smooth Muscle Cells (HASMCs), and Human
Aortic Adventitial Fibroblasts (HAAFs) were provided by
ScienCell Research Laboratories (Carlsbad, CA, USA). The
supplier company guaranteed the cells characteristics we required
via Cell Applications Inc. (San Diego, CA, USA).
For the adhesion studies, 2 × 104 human intravitally pre-
stained cells were separately seeded onto SilkGraft samples.
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HCAECs were seeded onto the inner ES layer, whereas HASMCs
or HAAFs were seeded onto the outer ES layer. In parallel,
the three cell types were separately seeded on 2D polystyrene
plates as controls. All the tests were performed in triplicate and
repeated in three separate experiments. Cell cultures were kept
in an incubator at 37◦C in 95 vol% air plus 5 vol% CO2. The
growth media used were: HCAECs, ready to use Endothelial Cell
Medium; HAAFs, Fibroblast Medium; HASMCs, SmoothMuscle
Cell Medium (all from ScienCell Research Laboratories, USA).
Every 3 days the growth media were changed with fresh ones and
the cell-conditioned media collected and stored at −80◦C to be
subsequently analyzed. The cultures were kept going for at least
20 consecutive days.
Cells Counts
Cells counts on polystyrene plates were first performed using an
inverted light microscope (IM35, Zeiss) (Armato et al., 1986).
On the same samples, cell number was determined by means
of the Cell Titer-Blue R© Cell Viability Assay (Promega, USA)
fluorescence assay based on the ability of living cells to convert a
redox dye (resazurin) into a final fluorescent product (resorufin).
Correlating microscopic findings with resorufin Promega assay
data allowed to construct cell type-specific standard curves to be
used to determine total cell numbers on SilkGrafts.
Assays of Cell Metabolites
Three metabolites (D-glucose, L-glutamine, lactate) were assayed
in the cell-conditioned growth medium samples from each of
the three types of cells separately cultured on SilkGraft or on
polystyrene surfaces. The data corrected for actual cell numbers
were expressed as means ± SE of the respective time-related
cumulative curves.
Cell D-glucose consumption was assessed by means
of a glucose oxidase assay using the Amplex R© Red
Glucose/Glucose Oxidase Assay Kit (Invitrogen-USA). L-
glutamine uptake/consumption was determined using the
L-glutamine assay kit developed by Megazyme (Ireland). The
lactic acid release was assessed via the colorimetric enzymatic
Lactate Assay Kit (Sigma Aldrich).
Assay of the Extracellular C-Telopeptide of
Procollagen Type I
The extracellular release (and subsequent assembly of fibers) of
type I collagen was assessed by evaluating the amount of the C-
telopeptide, which is released into the cell-conditioned growth
medium in stoichiometrically equal amounts from precursor
procollagen type I molecules. The samples were assayed using
the EIA kit developed by Takara Bio Inc. (Shiga, Japan). The
sensitivity of this assay is 10 ng/ml.
Human Proinflammatory Cytokines and Chemokines
Antibody Array
The secretion of various cytokines/chemokines into the growth
medium was assessed by using the Human Inflammation
Antibody Array, C-Series (RayBiotech-USA) in three distinct
experiments. In detail, 1.0ml medium sampled between day 18th
and 20th, was used. After a treatment for 60min with blocking
solution (Odissey Blocking BufferTM (LI-COR)with 0.05%Tween
20), the cytokines and chemokines antibody array membranes
were incubated with the medium samples overnight at 4◦C. Next,
the membranes were washed and incubated at room temperature
for 2 h with 1.0ml of primary biotin-conjugated antibody diluted
1:250 in blocking solution. This was followed by an incubation
at room temperature for 1 h with 2ml of DyLight800-Labeled
streptavidin (KPL, USA) diluted 1:7,500 in blocking solution.
The immunofluorescent signals were acquired by means of
an Odissey ImagerTM (LI-COR) scanner and quantified using
the Image StudioTM software. The resulting intensity values
from each array were normalized per 1,000 cells grown on
either substrate. The array kit sensitivity is 4–25 pg/ml and the
coefficient of variation of the intensity of the spots is 5–10%.
Hemocompatibility
The interaction between SilkGraft and blood components, i.e.,
the activation of the complement cascade and the alteration of
the leucocyte count, the changes on erythrocyte count, and the
presence of hemolysis, was studied according to the ISO 10993-
4:2017 standard. As suggested by the regulation, the induction
of thrombosis was assessed during the in vivo pilot trials. The
tests reported below were performed in compliance with Good
Laboratory Practices.
Activation of the Complement System
SilkGraft was incubated in human serum at 37 ± 1◦C for
90min with a surface/volume ratio of 3 cm²/ml. Zymosan A
from Saccharomyces cerevisiae served as positive control, human
serum alone as negative control and polypropylene material
as negative reference material. Serum Complement Membrane
Attack Complex (Sc5b-9) and Complement Component 3 (C3a)
concentrations were determined with a commercial ELISA
(MicroVueTM SC5b-9 Plus EIA and MicroVueTM C3a Plus EIA,
Quidel Corporation).
Hemolysis
The blood was collected from three adult rabbits in test tube
with anti-coagulant Sodium Citrate 3.2% (ratio 1+9 v/v Sodium
Citrate/Blood). Equal quantities of blood from each rabbit were
pooled and diluted with Mg- and Ca-free PBS to obtain a final
hemoglobin concentration of 1,000 mg/dl.
For indirect contact assay, SilkGraft samples were dipped
in Mg- and Ca-free PBS in order to reach a surface/volume
ratio of 3 cm2/ml and incubated for 72 h at 50 ± 2◦C. Seven
milliliter of extract were added to 1ml of diluted rabbit blood.
For direct contact assay, SilkGraft samples were dipped in diluted
rabbit blood and in Mg- and Ca-free PBS in order to reach a
surface/volume ratio of 3 cm2/ml for SilkGraft/PBS and 0.14
ml/ml for diluted blood/PBS. Negative control (USP reference
standard high-density polyethylene), positive control (water for
injection) and blank (PBS) were tested.
All the samples (direct and indirect contact) were incubated
in a water bath for 3 h at 37 ± 1◦C and agitation was inverted
twice every 30min. After centrifugation at 800G for 15min, the
concentration of hemoglobin in the supernatant was determined
with the automatic chemistry analyzer Konelab 20 (DASIT).
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Hematology
The effect of SilkGraft on red blood and white blood cells counts
was evaluated after immersion in human whole blood in order
to reach a surface/volume ratio of 3 cm2/ml and incubation for
15min at 37 ± 1◦C under dynamic conditions. An automatic
counter Sysmex KX-21N (DASIT) was used. As control, the
remaining part of the blood that did not come in contact with
SilkGraft was used.
In vivo Animal Pilot Studies
Animal Care
Pilot animal experiments were performed at NAMSA (Lyon,
France), an AAALAC internationally accredited firm. The study
protocol was approved by the NAMSA Ethical Committee
and the French Ministry of Education, Higher Education, and
Research. The study conditions conformed to the guidelines
of the European Union’s Directive EU/2010/63 for animal
experiments. One sheep (Blanche du Massif Central) and one
minipig (Göttingen) were used. Animals were kept under
controlled conditions. The animal housing room temperature
and relative humidity were recorded daily. Staff involved was
properly qualified and trained. Standard veterinary medical care
was also provided.
Pharmacological Treatment
Starting 3 days prior to the operation, the animals received daily
antiaggregant treatment (sheep: oral acetylsalicylic acid, Bayer;
minipig: Clopidogrel, Sanofi) to prevent thrombosis. Twenty
hours before surgery the animals were weighed and Enrofloxacin
(5% Baytril R©, Bayer) and/or Amoxicillin (Duphamox R© LA,
Zoetis) were administered. After anesthesia was induced, heparin
(Heparin Choay R©, Sanofi) was injected into the femoral artery
via an introducer sheath and Activated Clotted Time (ACT)
was evaluated using a Hemochron Junior 2 (International
Technidyne Corp., USA) instrument. Analgesic, anti-
inflammatory drugs and antibiotic treatments were administered
during surgery and the follow up period. Animals were also
maintained under prophylactic anticoagulant/antiaggregant
therapy for the 4 weeks of observation until termination.
Surgical Grafting Procedure and Follow-Up
A 2.5 cm (minipig) or 8.0 cm (sheep) segment of the carotid
artery was excised and replaced by end-to-end anastomosis with
a piece of sterilized SilkGraft (nominal 5mm inner diameter)
of corresponding length. Surgery was unilateral in the minipig
and bilateral in the sheep. Angiography and doppler ultrasound
controls were performed before and after the grafting procedure
and just prior to sacrifice using Iomeron 400 (Bracco Imaging,
France) as contrast medium.
After surgery, the animals were transferred to a recovery area
and monitored for 1 h prior to be brought back to their housing.
The supply of water and food was reinstalled. Animals were
monitored for 4 weeks and then euthanized.
Histopathology
At autopsy, the grafts, their connected carotid stumps, and
surrounding tissues were excised, endoluminal blood was
removed from the carotids by gently flushing it out first with
heparinized saline and then with 10% neutral buffered formalin
(NBS). To complete fixation explanted samples were dipped into
10% NBS. The fixed tissues were dehydrated in ethanol solutions
of increasing strength, cleared in xylene, and embedded in
paraffin. Microtome sections (4–7µm thick) were cut from each
paraffin block for histopathological analysis. After removing the
paraffin and rehydrating, the sections were stained with Safranin-
Hematoxylin-Eosin (SHE). Histopathology analysis concerned
graft endothelialization, intimal hyperplasia, thrombi, graft
recellularization, potential occlusion and the presence and type
of inflammatory cells.
Statistical Analysis
Data were expressed as mean values ± SE and their level of
statistical significance assessed by means of one-way ANOVA
followed by Holm-Sidak’s post hoc test. A P < 0.05 was taken
as significant.
RESULTS
Morphological, Chemical, Physical, and
Mechanical Characterization
The SilkGraft device (Figure 1A) is a hybrid tubular structure
consisting of two electrospun (ES) layers (inner and outer) and
an intermediate textile (TEX) layer (Figures 1B,C). It is made of
pure SF, present in the final device in form of native microfibers
(TEX) with an average diameter of 12–14µm (Figure 1D), and
electrospun nanofibers (ES), whose diameter falls in the 400–
600 nm range (Figure 1E) (Marelli et al., 2009).
To verify whether the processing steps, including the
sterilization with EtO, altered the chemical structure and
properties of the constituent biopolymer, the amino acid
composition of the sterilized SilkGraft device, as well as that
of two constituent materials, i.e., TEX microfibers, and ES
nanofibers, was determined and compared to that of native
SF microfibers. The results demonstrated that there were no
differences in the amino acid composition, indicating that neither
processing conditions nor sterilization with EtO (Zhao et al.,
2011) altered the intrinsic properties of SF materials (Table S1).
Structural properties of SilkGraft were characterized by ATR-
FTIR. The spectra of TEX microfibers and ES nanofibers
(Figure 1F) display the typical profile of β-sheet crystalline
materials (Marelli et al., 2010; Chiarini et al., 2016), as indicated
by the position, shape, and intensity of the Amide bands (Amide
I at 1,620 cm−1, with shoulder at 1,691 cm−1; Amide II at
1,512 cm−1; Amide III at 1,227 cm−1, and 1,262 cm−1). The
crystallinity index of ES nanofibers, expressed as intensity ratio
between the two Amide III components at 1,227 and 1,262 cm−1
(CI = I1227/I1262), was 0.58 ± 0.03, close to that determined on
native SF microfibers (CI ∼= 0.60) (Chiarini et al., 2016), thus
confirming the completion of the conformational transition from
a prevalently random coil structure of as-spun nanofibers to a
fully crystallized SF material.
Thermal properties of SilkGraft were investigated by DSC
analysis. Thermograms of TEX microfibers, ES nanofibers,
and final tubular device are shown in Figure 1G. TEX
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 6 November 2019 | Volume 7 | Article 356
Alessandrino et al. Small Caliber SF Vascular Graft
FIGURE 1 | Morphological and physico-chemical structure of SilkGraft. (A) Picture of a SilkGraft device with 5mm nominal inner diameter (ruler in mm). (B) SEM
cross-section of the graft showing the two inner and outer ES layers that enclose the intermediate TEX layer (scale bar, 1mm). (C) Detail of (B) showing a
magnification of the wall structure (scale bar 20µm). (D) TEX layer coupled to an ES layer, visible in the background. The texture of the braided mesh is characterized
by the presence of voids (scale bar 100µm). (E) SEM detail of SF nanofibers of the ES layer (scale bar, 3µm). (F) ATR-FTIR spectra of TEX and ES layers in the
2,000–800 cm−1 range. (G) DSC thermograms of TEX layer, ES layer, and SilkGraft finished device (marked ES-TEX-ES) in the 150–400◦C temperature range.
TABLE 1 | Geometrical and mechanical properties of SilkGraft (nominal Øinner = 5mm).
Wall thickness (mm) Unit weight (mg cm−1) Weight (%) Circumferential tensile tests Burst pressure (mmHg)
ES layers TEX layer Breaking Load (N) Strain at break (mm/mm)
0.59 ± 0.03 11.9 ± 0.5 61 ± 2 39 ± 2 29.5 ± 1.0 1.60 ± 0.05 2,308 ± 88
microfibers displayed a high thermal stability, with a main
endothermic transition peaking at about 320◦C, attributed
to melting/degradation of highly crystalline and oriented SF
microfibers (Chiarini et al., 2016). ES nanofibers, as many other
regenerated SF materials, showed a marked low-temperature
shift of the same transition, with a peak at about 289◦C (Marelli
et al., 2010). The DSC profile of the SilkGraft device was the
sum of the individual components, with two discrete peaks
corresponding to the thermal transitions of ES and TEX layers.
The enthalpy associated with the thermal degradation of TEX
(1H=−402± 41 J/g) and ES (1H=−307± 32 J/g) was used to
estimate the weight contribution of each component in the final
device. ES nanofibers account for about 60% by weight, while the
remaining 40% is represented by the TEX layer (Table 1).
Geometrical parameters and mechanical properties of
SilkGraft with a nominal inner diameter of 5mm are listed in
Table 1. The weight per unit length of the device is very low,
about 5 times lower than that of a commercial ePTFE vascular
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FIGURE 2 | Time dependence of the absolute cell numbers of HAAF (A), HASMC (B), and HCAEC (C) cells cultured on SilkGraft and on polystyrene. Absolute cell
numbers were lower on SilkGraft than on polystyrene because the available surface area was reduced due to the use of the steel ring which kept the silk substrate
under water. Total cell growth differences between cells cultured on SilkGraft or on polystyrene are expressed by the areas under the corresponding curves, the
statistical levels of significance of which are: for HAAFs, P < 0.001; for HASMCs, P < 0.01; and for HCAECs, P < 0.001.
graft with similar inner diameter and wall thickness. While
the ePTFE graft has a full thickness wall, the middle TEX layer
of SilkGraft shows the typical structure of a braided mesh,
with many voids that contribute to make the structure lighter
(Figure 1D). The values of breaking load, which are about 30
times higher than those of similar grafts made only of electrospun
SF nanofibers (Marelli et al., 2010), confirm that the TEX layer
is the load bearing component of the graft. The contribution
of the ES layers, which are solidly attached to the TEX layer
through numerous welding points, is negligible. The results of
burst pressure further confirm the significant contribution of the
TEX layer to the mechanical performance of the multi-layered
graft. The value of 2,308 mmHg is significantly larger than that of
electrospun SF tubes with the same diameter (Marelli et al., 2010)
and of the same order of magnitude of the values reported for
internal mammary artery (3,196± 1,264 mmHg) and saphenous
vein (1,599± 877 mmHg) (Konig et al., 2009).
In vitro Biocompatibility Studies
The biocompatibility of SilkGraft was tested using the three most
representative cell types of human peripheral arteries, namely
endothelial cells (HCAECs), smoothmuscle cells (HASMCs), and
adventitial fibroblasts (HAAFs). To assure the full significance
and relevance of the results, we chose and applied a stringent
set of selective criteria. To be eligible, the human cells had
to originate from disease-free human subjects, to be of recent
isolation (i.e., within the second passage in vitro), to be free from
contaminating cells of other types, to be diploid and unprocessed,
to be free from viral infections (particularly HIV-1, HHVB,
HHVC), and to express cell type-specific markers.
Cell Adhesion, Survival and Proliferation Studies
DilC18(3) or DiOC18(3) intravitally stained cells were carefully
seeded on the internal (HCAECs) or external (HASMCs or
HAAFs) surfaces of SilkGraft and, in parallel, onto polystyrene.
Next, the fluorescent cells were observed daily under an inverted
microscope for up to 3 weeks of staying in vitro. Examples of
the three types of cells grown on SilkGraft and on polystyrene
substrates are shown in Figure S1. An adhesion fraction of
61 ± 5% for each cell type was detected 3 h after seeding,
which was 2.1-fold (P < 0.001) the fraction of the same
cells adhering to polystyrene surfaces at the same time point.
Morphological indicators of apoptosis (e.g., cells with a shrunk
or blebbing cytoplasm and substrate-adhering or free-floating
spherical apoptotic bodies) were very rarely observed. Alike
data were reported previously in the case of human dermal
fibroblasts isolated from adult subjects and grown on SF-covered
poly(carbonate)-urethane vs. polystyrene (Chiarini et al., 2003).
Our present findings show that with respect to a polystyrene
surface, SilkGraft neatly favors the adhesion of isolated human
cells. As is well-known, adhesion to a substrate favors the survival
and growth of untransformed (normal) cells.
The absolute numbers of each cell type grown on either
substrate are shown and compared in Figure 2. Throughout 20
days HAAFs seeded onto SilkGraft increased their number by 4-
fold, HCAECs by 3-fold, and HASMCs by 6.5-fold (P < 0.001 vs.
0 time in all instances). On polystyrene, the increases in numbers
of the same cell types were greater, i.e., 7.5-fold for HAAFs, 5-
fold for HCAECs, and nearly 7-fold for HASMCs (P < 0.001
vs. 0 time in all instances). However, if data are normalized
to the apparent surface area available for growth (lower on
SilkGraft due to the steel ring applied onto its surface), after
20 days HAAFs and HASMCs reached significantly (P < 0.001)
greater cell densities on SilkGraft than on polystyrene, whereas
HCAECs densities were similar between the two substrates
(P > 0.05) (Table 2).
Evaluation of Cell Metabolism
The results concerning the studies on glucose and glutamine
consumption, and the extracellular release of lactate were
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normalized per 1,000 cells and are reported in Figure 3 and
Table 3. CumulativeHAAFs consumption of glucose on SilkGraft
was greater than on polystyrene, the difference being much
TABLE 2 | Living cells density/mm2 of apparent surface area after 21 days of in
vitro culture.
Cell type Polystyrene (PS) plate SilkGraft (SF) Ratio SF/PS
HAAFs 363 ± 31 692 ± 63* 1.9 ± 0.1*
HASMCs 366 ± 28 1222 ± 106* 3.3 ± 0.2*
HCAECs 254 ± 23 232 ± 19ns 0.91 ± 0.1ns
Data are normalized to the apparent surface area available for growth. Levels of statistical
significance of the differences between the values on SilkGraft and on polystyrene:
*P < 0.001; ns, P > 0.05.
more remarkable during the first 12 days of culture in vitro
(Figure 3A). Conversely, the cumulative HAAFs consumption
of glutamine on polystyrene was greater than on SilkGraft
(Figure 3D), the difference becoming remarkable only after
the first 12 days. On the other hand, the release of lactate
into the medium was the same whichever the substrate
considered (Figure 3G).
HASMCs cumulative consumption of glucose (Figure 3B) and
glutamine (Figure 3E) and the release of lactic acid into the
medium (Figure 3H) were not significantly affected by their
attachment to either substrate.
Glutamine oxidation is the main source of energy for
HCAECs. On SilkGraft the cumulative consumption of
glutamine was typically much higher than on polystyrene
(Figure 3F). The cumulative consumption of glucose was
FIGURE 3 | Cumulative consumption of glucose and glutamine and release of lactate. Results were normalized per 103 cells. (A–C) The cumulative glucose
consumption was higher for HAAFs (P < 0.05) and HCAECs (P < 0.001) seeded on SilkGraft, whereas it showed only marginal differences between the two
substrates for HASMCs (P > 0.05). (D–F) Glutamine consumption was lower for HAAFs (P < 0.05) seeded on SilkGraft, similar for HASMCs (P > 0.05) cultured on
the two substrates, and significantly larger for HCAECs (P < 0.001) grown on the silk substrate. (G,H) The cumulative amount of lactate released by HAAFs and
HASMCs was the same whichever the substrate (P > 0.05). Lactate release could not be assessed for HCAECs because the released lactate was re-uptaken and
used for metabolic purposes. The statistical analysis of these data is shown in Table 3.
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TABLE 3 | Comparison of metabolic parameters* of the different cell types
cultured on SilkGraft and polystyrene.
Polystyrene SilkGraft 1% P
HAAFs
Glucose uptake 1.642 ± 0.098 2.122 ± 0.150 +29.2 0.021
Glutamine uptake 0.316 ± 0.013 0.251 ± 0.012 −20.6 0.003
Lactate release 14.664 ± 0.783 13.947 ± 0.545 −4.9 0.465
Procollagen C-Telopeptide 1.500 ± 0.078 0.993 ± 0.072 −33.8 <0.001
HCAECs
Glucose uptake 0.368 ± 0.026 0.572 ± 0.039 +55.4 <0.001
Glutamine uptake 0.919 ± 0.083 2.504 ± 0.198 +172.4 <0.001
HASMCs
Glucose uptake 0.336 ± 0.030 0.385 ± 0.032 +14.6 0.276
Glutamine uptake 0.794 ± 0.042 0.807 ± 0.041 +1.6 0.827
Lactate release 4.016 ± 0.311 4.652 ± 0.328 +15.8 0.181
*The parameters are the areas under the respective cumulative curves shown in
Figures 3, 4.
also greater than on polystyrene (Figure 3C). Undetectable
levels of lactate were released into the medium by HCAECs,
whichever the substrate considered, due to the known fact
that endothelial cells can uptake and use lactate as an
additional source of energy (Krützfeldt et al., 1990; Vegran
et al., 2011).
Synthesis of Type I Collagen by HAAFs
Type I procollagen synthesis is a specific biomarker of HAAFs
(Dal Prà et al., 2006). The release of the C-telopeptide of
the procollagen is a stoichiometric index of the amount of
collagen type I secreted, which subsequently undergoes fiber
assembly. Thus, when HAAFs were grown on SilkGraft their
cumulative release of C-telopeptide significantly decreased vs.
that on polystyrene (Figure 4). A quantitative comparison
of type I collagen synthesis on the two substrates is listed
in Table 3.
Cytokine and Chemokine Expression
After 20 days of staying in vitro, each cell type exhibited its
own specific pattern of secreted cytokines and chemokines
(Figure 5). No substantial qualitative differences emerged
when comparing the expression patterns of each cell
type in relation to the culture substrate. However,
substrate-related significant differences in the quantitative
secretion of some cytokines and chemokines could
be detected.
HAAFs seeded on SilkGraft exhibited a higher secretion
of IL-6 (+22%), MCP-1 (+13%), and TIMP-2 (+19%),
whereas IP-10 (−26%), MCP-2 (−50%), Eotaxin-1 (−41%),
and RANTES (−72%) were released at lesser extent than
on polystyrene.
HCAECs grown on SilkGraft released higher amounts of IP-
10 (+43%), MCP-1 (+27%), and TNF-β (+84%) as compared to
polystyrene. RANTES and IL-6 were released to a lesser extent,
while TIMP-2 and MIP-1β did not change significantly between
the two substrates.
FIGURE 4 | The cumulative assembly of collagen type I (indirectly measured
as the stoichiometrically released C-telopeptide of procollagen) was
significantly (P < 0.001) lower for HAAFs cultured on SilkGraft than on
polystyrene surfaces. Results were normalized per 103 cells. The statistical
analysis of these data is shown in Table 3.
Finally, HASMCs discretely secreted a wider set of
cytokines/chemokines. Interestingly, GM-CSF (+766%),
MCP-2 (+557%), IL-1α (+561%), IL-1β (+390%), and Eotaxin-1
(+315%) were secreted at much higher levels on SilkGraft than
on polystyrene, the secretion of ICAM-1 and RANTES only
raised by +30%, whereas the release of IL-6, MIP-1β, TIMP-2,
MCP-1, and IP-10 fell by −10/30% vs. the corresponding levels
on polystyrene.
Hemocompatibility
Regarding the complement activation, a statistically significant
increase (p < 0.05) in Sc5b-9 was noted (Table S2). However, the
Sc5b-9 values of SilkGraft were still inside the range of the control
data of a normal standard population (334–1,672 ng/ml). Based
on this, the increase was regarded as not biologically relevant. The
C3a concentration was comparable to that of the negative control
(Table S2). In conclusion, it can be stated that SilkGraft did
not induce a biologically relevant activation of the complement
system. Both indirect and direct contact hemolysis assays showed
that SilkGraft exerted no hemolytic activity (hemolytic indexes<
2%) (Table S3). SilkGraft did not cause any alteration of red and
white blood cells counts because the difference with the respective
controls was <4 and <7%, respectively (Table S4).
Pilot Animal Studies
The purposes of the pilot studies were first to assess which
animal model would be better to use for future medium-to-long
term trials, and then to establish the suitability of the surgical
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FIGURE 5 | Relevant cytokines and chemokines secreted by each cell type cultured between 18 and 20 days on SilkGraft and polystyrene: HAFFs (A), HCAECs (B),
and HASMCs (C). Results of immunofluorescence intensities were normalized to 103 cells. IL-6: Interleukin-6; MCP-1: Monocyte chemoattractant protein-1; TIMP-2:
Tissue inhibitor of metal proteinases-2; IP-10: Interferon gamma-induced protein-10; MCP-2: Monocyte chemoattractant protein-2; Eotaxin-1; RANTES: Regulated on
activation normal T cell expressed and secreted; MIP-1β: Macrophage inflammatory protein-1β; TNF-β: Tumor necrosis factor-β; GM-CSF: Granulocyte-macrophage
colony stimulating factor; IL-1α: Interleukin-1α; IL-1β: Interleukin-1β; ICAM-1: Intercellular adhesion molecule-1. The bars are the mean values of three independent
experiments corrected for cell numbers. *P < 0.01; **P < 0.001. SEMs, not shown, ranged between 5 and 10% of corresponding mean values.
model, to evaluate handling characteristics, aptness to stitching,
patency, formation of thrombi, first signs of degradation, local
tissue effects, and the general performance of SilkGraft. Resected
portions of the carotid arteries of one minipig (unilateral) and
one sheep (bilateral) were replaced with SilkGraft, the animals
were sacrificed 4 weeks later, and histopathology of explants
was examined.
Surgery was done without major difficulty on both minipig
and sheep. SilkGraft preparation, handling, stitching suitability,
and anastomosis capacity were overall considered as good.
Moderate bleeding at the suture holes was observed. The
animals survived for 4 weeks with no unwanted side effects
prior to be euthanized. No graft-related clinical or macroscopic
abnormalities were noted at the site of implantation or
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FIGURE 6 | Histopathogical analysis of a SilkGraft stitched end-to-end on the carotid artery of minipig and sheep 4 weeks after grafting. Staining:
Safranin-Hematoxylin-Eosin. Minipig: (A) Longitudinal cut in correspondence of the proximal anastomosis showing a pervious lumen (A, anastomotic line).
(B) Representative cross-sectional cut of the central part of the graft. The lumen is pervious, though moderately reduced by an intimal hyperplasia. (C) Detail of the
graft wall: perivascular cell infiltrates are visible; the inner and outer ES layers appear compact, whereas the TEX layer is penetrated by growing vessels and
collagen-producing fibroblasts; endothelialization is visible at the inner graft surface. Sheep: (D) Typical longitudinal sections of the proximal end-to-end anastomotic
sites (A, anastomotic line); the lumen is pervious and devoid of any stenosis. Endothelization is restricted to a 3 mm-wide area beyond the anastomosis. (E)
Representative cross-section of the central part of the graft; the lumen is pervious while endothelization, neointimal hyperplasia, and stenosis are absent. (F) Detail of
the graft wall: an inflammatory infiltrate envelops the graft; a newly-formed vascularized connective tissue only partly colonizes the middle TEX layer.
in distant organs during the test period. Ultrasound and
angiographic examination at day 13 and 24 after surgery
showed patent carotids, no aneurysm, dilation, dissection, blood
collection or signs of infection. No stenosis was identified
for the sheep, whereas a slight stenosis near the proximal
anastomosis was identified for the minipig. Normal blood
flow was also noted at termination. The external surface
of the grafts explanted from the sheep was covered by a
moderate amount of thin and soft tissue, while that recovered
from the minipig was surrounded by a thicker layer of
soft tissue.
The histopathological analysis of the minipig explant showed
that inside the graft and its attached carotid stumps the lumen
was still pervious and totally devoid of thrombi (Figure 6A).
Histopathology also confirmed the presence of a slight yet
diffuse stenosis of the graft’s lumen (Figure 6B). Endothelial-
like cells lined the whole surface of the newly-formed graft’s
intima (Figure 6C). Collagen fibers, fibroblasts, macrophages,
and multinucleated giant cells together with a lesser number of
lymphocytes, plasma cells, and neutrophils filled the voids of the
middle TEX layer. Colonizing cells circumferentially infiltrated
the graft’s outer nanofibrous ES layer. Moreover, the abundant
periarterial tissue was infiltrated by lymphocytes and plasma cells.
Altogether, these features suggested an ongoing foreign body
response (FBR), as reported for other SF-based scaffolds (Dal Prà
et al., 2005; Chiarini et al., 2016).
Grafted sheep carotids were pervious to blood flow and did
not show any luminal stenosis (Figures 6D,E). Endothelization
was restricted to a 3 mm-wide area beyond the end-to-end
anastomotic sites. Only a thin fibrin layer and marginated
leukocytes adhered to the remaining inner nanofibrous
surfaces of the grafts. Also, differently from the minipig,
in the long portion of the graft intervening between the
anastomotic sites no newly-formed neointimal connective
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tissue was present. The middle TEX layer was only partially
colonized by newly-formed vascularized connective tissue
(Figure 6F). A thick infiltrate made up by lymphocytes,
mononuclear macrophages, polynucleated giant cells, and
neutrophils enveloped the graft’s external nanofibrous layer,
being less crowded around the proximal and distal arterial
stumps. This picture indicated an ongoing FBR, but with
no concurring subendothelial hyperplasia and no damage to
neighboring tissues.
DISCUSSION
Electrospun scaffolds may suffer from some limitations when
biomimicry must be coupled with a high level of mechanical
performance, such as in the case of vascular grafts. An
affordable solution is therefore to couple electrospinning and
textile technologies (like weaving, knitting, braiding, etc.), with
the aim to take advantage of both of them for realizing
biomimetic scaffolds able to withstand mechanical stresses in
tensile, compression, and bending modes. Zhang et al. (2017)
reported the fabrication of a three-layered vascular graft where
the intima and media layers were obtained by sequentially
electrospinning SF and poly(L-lactide-co-ε-caprolactone), while
the outer adventitia-like layer was built up by braiding SF yarns.
In another study (Mi et al., 2015), a polyurethane (PU)/SF
three-layered small diameter tubular scaffold was fabricated
by combining electrospinning (inner PU layer) and braiding
(middle SF layer) technologies. In addition, a spongy PU layer
was built as third outer layer by molding and freeze drying.
Both scaffolds underwent extensive mechanical and in vitro
cytocompatibility characterization, but no in vivo functional tests
were reported.
Coupling electrospun and textile SF matrices for the
production of multi-layered tubular scaffolds is recognized
as a valid approach to overcome bottlenecks due to lack of
mechanical attributes of the electrospun SF scaffolds. However,
the achievement of a strong adhesion between electrospun and
textile layers might be a challenge, because textile surfaces onto
which electrospun fibers are deposited are not homogenously
flat, but present microscopic rough or sunken sites that
prevent a continuous contact between the two surfaces. This
results in poor adhesion strength, as demonstrated by the
fact that the electrospun layer can be easily peeled off by
applying a mild strength. Risks associated with poor adhesion
between electrospun and textile layers may have very serious
consequences on the performance of an implantable device,
such as creation ofmorphological andmechanical discontinuities
between layers, yielding and/or collapse of weaker layers, loss
of geometric characteristics, thus leading to ultimate failure,
especially under the stressing working conditions experienced
in vivo.
To overcome these problems, we have developed an
advanced manufacturing technology aimed at achieving an
effective hybridization between electrospun and textile matrices
(Alessandrino, 2016). Coating of the TEX surface with the ionic
liquid before electrospinning ensures perfect welding between
the electrospun and textile matrices. In fact, as soon as the
first electrospun fibers reach the TEX surface, the still plastic
fibers melt in contact with the ionic liquid. A dense network
of strong welding points between the growing electrospun layer
and the textile substrate is created. Adhesion tests showed that a
force of 0.5–1N is needed to peel off one layer from the other
(Alessandrino, 2016). Therefore, the multi-layered wall of the
tubular scaffold behaves as if it were made of a single piece,
while harmonizing the high resistance to mechanical stresses of
native SF microfibers with the enhanced biomimicking attitude
of regenerated SF nanofibers. The load bearing component
is the TEX layer, which confers a high mechanical resistance
on the device. When stressed under wet conditions the inner
and outer ES layers become very elastic. Under increasing
load, they undergo extensive stretching deformation without
fracturing or breaking. Interestingly, ES and TEX layers remain
strongly attached to each other until the ultimate breaking point
is reached, thus confirming the effectiveness of the patented
coupling technology, which allows the formation of a dense
network of welding points between the ES layers and the meshes
of the TEX layer.
The production technology allows the fabrication of SilkGraft
in a wide range of inner diameters, overlapping those of
currently marketed small caliber synthetic vascular grafts.
Compared to available ePTFE and PET vascular devices,
SilkGraft is characterized by a design which results in a light
but mechanically resistant structure. The light weight is likely
to bring biological advantages because the burden of foreign
material at the site of implantation is significantly reduced,
thus avoiding excessive stresses to surrounding tissues during
remodeling. This feature doesn’t seem to negatively impact on
the mechanical performance, as demonstrated by the values
of circumferential breaking load and burst strength. In fact,
if the breaking load reported in Table 1 is normalized to
the cross-section surface, a stress value of about 3 MPa is
obtained, which underestimates the real value due to the
open texture of the wall of the device (see: Figure 1D).
The stress value is significantly larger than that reported
for the human descending mid-thoracic aorta with roughly
similar inner diameter (1.72 ± 0.89 MPa) (Mohan and
Melvin, 1982). Interestingly, the value of strain falls in the
same range of that reported for human aorta (1.53 ± 0.28)
(Mohan and Melvin, 1982).
The manufacturing protocol of SilkGraft includes various
washing treatments with hydro-alcoholic solutions, which are
aimed not only at achieving the complete removal of processing
aids, but also at consolidating as-spun SF nanofibers that are
still prevalently amorphous and more sensitive to physical,
(bio)chemical, and mechanical stresses. The IR crystallinity
index confirmed that nanofibers in the final device are fully
crystallized. Actually, this structural feature is very important for
the functionality of the device because, according to unanimous
consensus, the degree of crystallinity of regenerated SF scaffolds
strongly impacts on the rate of in vivo biodegradation (Thurber
et al., 2015). In our case, the nanofibers are expected to
undergo remodeling in the medium term, while in the meantime
supporting neo-vascular tissue formation. To this purpose, fully
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crystalline ES nanofibers are more favorable to ensure a slow
degradation rate in the biological environment.
The results of the in vitro studies on SilkGraft showed a
high biocompatibility of the device, which was evaluated by
seeding the three main types of cells inhabiting the arterial wall
(HCAECs, HASMCs, and HAAFs). Cell adhesion to SilkGraft
was in all instance superior to polystyrene, in keeping with
previous observations (Chiarini et al., 2003; Dal Prà et al.,
2006). The preferential energy source for both HASMCs and
HCAECs was glutamine, while it was glucose for HAAFs (Wu
et al., 2000; Eelen et al., 2013). HAAFs and HASMCs also
secreted large amounts of lactic acid into the medium, whereas
HCAECs released none. This occurred becauseHCAECs have the
metabolic capability to convert lactate into pyruvate and to use
it for oxidative metabolism, thus saving glucose which they cede
to the surrounding tissues (Dal Prà et al., 2005; Chiarini et al.,
2016). It should be noted that the cumulative curves of consumed
glucose and glutamine and of released lactate proper of HAAFs
and HASMCs exhibited similar patterns, matching the metabolic
activities and the expansion of the respective cell populations.
Notably, addition of serum suppresses the contact inhibition
of growth in HASMCs (Krützfeldt et al., 1990; Viñals and
Pouysségur, 1999). This may explain why they reached the
highest density when seeded on SilkGraft, which did not happen
for HCAECs. Moreover, the observed behavioral differences
could be due to unlike cell sizes (endothelial cells > fibroblasts
> smooth muscle cells), morphological features, and regulatory
mechanisms intrinsic to each cell type. In addition, the different
characteristics of SilkGraft and polystyrene surfaces, including
the adhesiveness for cells and the somewhat broader surface area
offered by the nanofibers, also had an impact. Having larger
sizes, the HCAECs seeded on the inner nanofibrous surface
reached the confluence and the contact inhibition of growth
at an earlier time and more permanently than the other two
cell types. This could be beneficial because in vivo HCAECs,
once they had reached confluence on the surface of the graft,
would stop proliferating and thus keep the lumen pervious to the
flowing blood. Moreover, according to our previous observations
concerning HAAFs grown on SF microfibers (Chiarini et al.,
2003), the present results strengthen the view that HAAFs
growing on an SF substrate significantly curtail their de novo
production of type I collagen, which translates into a remarkable
antifibrogenic upshot and could be significantly relevant in the
clinical settings. In other words, it can be concluded that the SF
substrate in a nanofibrous format exerts a neat antifibrotic effect
on HAAFs.
Some cytokines and/or chemokines are cell type-specific
biomarkers. The pattern of cytokines and chemokines secreted
into the growth medium under the conditions examined
would reveal the proliferative and/or pro-inflammatory
proclivities of the cells. In particular, released chemokines
may attract circulating leukocytes. Moreover, cytokines
and chemokines play important roles in several cellular
processes like growth, differentiation, apoptosis, angiogenesis,
inflammation, and innate immunity. Among the identified
cytokines and chemokines, IL-6 stands out, being the most
intensely secreted one by each of the three cell types both on
SilkGraft and on polystyrene. IL-6 is considered a biomarker
of cell proliferation, differentiation and survival (Morimoto
et al., 1991; Krishnaswamy et al., 1998; Kyurkchiev et al.,
2014). Similarly, the basal secretion of MCP-1 and/or MCP-2
is indicative of a cell proliferation capacity. MCP-1 promotes
the arteriogenesis associated with the induction of Vascular
Endothelial Growth Factor (VEGF)-A expression (Keeley et al.,
2008). Among the other important chemokines secreted by the
three cell types, we mention here IP-10, known for its antifibrotic
and angiostatic properties, and RANTES protein, known for
its ability to regulate leucocyte diapedesis, angiogenesis and
some scarring processes (Bujak et al., 2009; Lin et al., 2018). In
human aorta-derived SMCs, RANTES increased the expression
of cell cycle regulatory proteins and of markers of their synthetic
phenotype (Lin et al., 2018). GM-CSF is constitutively expressed
by HASMCs and an elevation in GM-CSF expression associates
with the HASMCs synthetic phenotype (Plenz et al., 1997). As
well, the cellular adhesion molecule ICAM-1 and the HASMCs
basal secretion of cytokines IL-1α and IL-1β can influence and
potentiate cellular proliferation by playing an autocrine role
(Braun et al., 1999; Schultz et al., 2007; Bonin et al., 2009). The
low secretion of TNF-β from HCAECs on polystyrene surged
significantly when the cells were grown on SilkGraft. Notably,
TNF-β signals control the proper development and maintenance
of endothelial cells (Zindl et al., 2009).
All the three cell types, once cultured on either SilkGraft
or polystyrene, exhibited similarly low basal levels of TIMP-2,
a metalloprotease blocker which regulates extracellular matrix
(ECM) remodeling processes and interactions between cells and
ECM, as well as cell proliferation by an autocrine mechanism
(Hayakawa et al., 1994). On the other hand, it is important to note
that no significant amounts of truly pro-inflammatory cytokines,
such as Tumor Necrosis Factor-α (TNF-α), or of profibrotic
cytokines, such as Transforming growth factor-β (TGF-β) were
secreted by any of the three cell types grown on either substrate.
Therefore, the patterns of cytokines and chemokines secreted by
the three cell types cultured on SilkGraft suggest a proliferative
attitude while neatly excluding a pro-inflammatory and/or pro-
fibrogenic proclivity.
The complement system is part of the innate immune system
and may be involved in promoting and accelerating hemolysis,
platelet and leukocyte activation and thrombosis on device
material surfaces, while hemolysis is the liberation of hemoglobin
following disruption of the erythrocytes. The hemocompatibility
assays demonstrated that SilkGraft did not activate the Sc5b-9
and C3a components of the complement system, did not result
in hemolytic effects, and did not alter the counts of red and
white blood cells. Moreover, no thrombi formation was observed
during the in vivo pilot trials. The latter parameter will be further
controlled during the on-going long-term studies (up to 1 year).
Finally, the pilot animal study showed the feasibility of using
SilkGraft as small caliber vessel graft in vivo. Due to the size of the
graft, a large animal model with vessels similar in size to human’s
was needed to allow appropriate placement and evaluation in
view of future clinical use. Both minipig and sheep are used as
appropriate animal models to evaluate performance, and local
tissue effects after vascular implantation (Byrom et al., 2010).
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Carotid implantation was chosen to mimic clinical use and to
avoid anatomical limitations (carotids are straighter and with
less branches than femoral arteries). Advantages associated with
using sheep as the animal model are: (i) blood vessels easily
accessible and more superficial; (ii) slower endothelialization,
more similar to human; (iii) ability to perform blood tests
and eco-doppler with animals awake, which translates into
the possibility to perform more exams with less stress for the
animal; and last but not least (iv) the sheep model allows
to evaluate a longer graft, up to 10 cm. Therefore, long-term
studies (up to 1 year) aimed at assessing the patency and wall
restructuration ability of the graft are already under course in
sheep, to demonstrate the feasibility of testing SilkGraft in human
clinical settings.
CONCLUSIONS
SilkGraft is a small caliber vascular graft entirely made of
pure silk fibroin. The fabrication technology was progressively
refined through recursive testing and optimization procedures
which led to a standardized production protocol. Particular
attention was devoted to the careful selection of startingmaterials
and processing aids (e.g., size of the SF yarn, texture and
mechanical performance of the TEX layer, chemical properties
and efficacy of the welding medium, etc.), as well as to fine-
tuning key processing parameters (e.g., electrospinning, strategy
of coupling TEX and ES layers, consolidation of the hybrid
structure, final purification before sterilization, etc.). The process
development led to a tubular device where the inner and outer
ES layers and the middle TEX layer are perfectly integrated at
the structural and functional level and respond as a single body
to mechanical stresses, without showing any mutual slipping
or separation. In fact, the main target was to manufacture
a multi-layered scaffold characterized by an easy handling
during surgery and, when implanted, able to achieve top level
biomimicking performance with the surrounding living tissues
while avoiding the onset of any biomechanical mismatch with the
native artery.
In vitro studies with three main types of cells inhabiting
the arterial wall, i.e., HCAECs, HASMCs, and HAAFs, showed
that SilkGraft exhibited a high degree of biocompatibility and
a level of cell adhesion superior to polystyrene. The trends
of specific metabolic markers, like consumption of glucose
and glutamine and release of acid lactic into the medium,
confirmed the intense metabolic activities and the expansion
of the cell populations cultured on SilkGraft coupled with
a curtailed production of collagen and with no secretion of
pro-inflammatory or pro-fibrotic cytokines and chemokines.
Furthermore, blood hemocompatibility was corroborated by the
lack of complement activation, hemolysis, and alteration of cell
counts assays.
The results of pilot animal studies indicated the sheep as the
model of choice to carry out the preclinical in vivo tests before
the clinical trials in humans and confirmed that the device is easy
to handle and surgically stitch. Finally, it is important to highlight
that in our setting, thanks to its promising biological responses,
SilkGraft is intended as an “off-the-shelf ” device, no longer
requiring pre-seeding with cells, thus eliminating related time
delays and costs and minimizing the steps for graft preparation
before implantation.
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